$CMPS earnings report

Compass remains a pre-commercial company focused on bringing COMP360 psilocybin treatment to the TRD market. The central operating development in the third quarter was that its rolling NDA submission was nearing completion, with the final submission expected in the next two weeks. Management said launch readiness remains on track for an expected H12027 launch, subject to FDA approval. The company also cited 52-week open-label COMP005 data and 6-month COMP006 data as reinforcing rapid onset, sustained durability and reproducibility of effect, while its late-stage PTSD trial remained underway.

Operating expenses were $ 56,437 for the three months ended September 30, 2026, compared with $ 40,536 in the prior-year period. Research and development expense declined to $ 23,458 from $ 27,325, reflecting lower clinical-trial costs following completion of the Phase 3 TRD program and lower discovery-program costs. Selling, general and administrative expense increased to $ 32,979 from $ 13,211, driven by commercial infrastructure, market access and reimbursement capabilities, supply chain readiness, and other launch preparation activities.

The reported third-quarter net loss was $ (9,831), compared with $ (137,717) a year earlier, but the release identifies warrant accounting as the primary driver of the improvement. Fair value change of warrant liabilities was a $ 40,782 gain in the 2026 quarter versus a $ (101,318) loss in the 2025 quarter. Loss from operations was $ (56,437), compared with $ (40,536), placing attention on the underlying increase in total operating expenses despite the materially smaller reported net loss.

Liquidity was $444.0 million of cash and cash equivalents as of September 30, 2026, compared with $149.6 million as of December 31, 2025. Debt was $51.0 million at September 30, 2026, compared with $31.6 million at December 31, 2025. Management guided that its current cash position is expected to fund operating expenses and capital expenditure requirements into 2028, framing the balance sheet around the NDA process, potential approval and launch preparation.

The near-term read centers on regulatory execution and commercialization readiness rather than revenue or margin delivery, neither of which was reported. The filing highlights the potential for a 1-2 month review period tied to the National Priority Voucher, but also explicitly states that the voucher and rolling review may not lead to a faster FDA review or approval process. The company is investing ahead of a potential launch while advancing the PTSD program, leaving regulatory outcomes, rescheduling, coverage and reimbursement as the principal stated execution dependencies.

Compass's reported period centered on advancing COMP360 toward regulatory filing and commercial preparation rather than on product revenue. The company said rolling NDA submission and initial review are underway, some NDA modules have been submitted, and completion of all modules remains on track for Q4. Commercial launch is expected in the first half of 2027, subject to FDA approval and DEA rescheduling. The Phase 3 program in TRD remains the central clinical asset, while a late-stage PTSD trial is underway.

Research and development expense was $29.2 million for the three months ended June 30, 2026, compared with $30.3 million for the same period in 2025. For the six-month period, research and development expense was $55.7 million compared with $61.2 million. Management attributed the decrease primarily to lower development expense as the Phase 3 TRD program progresses toward completion, along with reduced discovery expense following program terminations. The decrease was partly offset by higher facilities and other expense, primarily external consulting fees and contractors.

Commercial readiness is increasing the operating cost base. General and administrative expense was $23.2 million in the second quarter compared with $12.6 million in the prior-year period, and was $39.6 million for the first six months compared with $31.3 million. The company attributed the increase to costs supporting commercial preparedness. During the first half, Compass also expanded strategic collaborations with Radial and Osmind and focused on treatment ecosystem planning, including patient care pathways, provider experience, support-staff training, site economics and treatment-model optimization.

Reported net loss was $253.8 million, or $1.88 net loss per share, in the second quarter, compared with $38.4 million, or $0.41 net loss per share, in the comparable 2025 period. The stated primary driver was a $205.6 million loss from the change in fair value of warrants, compared with a $2.5 million loss in the prior-year quarter. Management specifically noted that warrant valuations fluctuate with the share price and can produce significant variability in reported net income or net loss. For the six months, net loss was $162.6 million, or $1.33 net loss per share, compared with $56.3 million, or $0.62 net loss per share.

Liquidity is the principal financial support for the development-to-launch transition. Cash and cash equivalents were $433.3 million as of June 30, 2026, compared with $149.6 million as of December 31, 2025, while debt was $50.7 million compared with $31.6 million. Compass guided that its current cash position is expected to fund operating expenses and capital expenditure requirements into 2028. Key execution points are completion of the Q4 NDA submission, regulatory review and rescheduling, and commercial operational readiness ahead of the expected first-half 2027 launch.